Joon Young Song, Ki Tae Kwon, Wan Beom Park, Ji Yun Noh, Sun Hee Park, Eun Ju Choo, Min Joo Choi, Jun Yong Choi, Jung Yeon Heo, Won Suk Choi
{"title":"免疫功能低下患者接种流感疫苗的建议。","authors":"Joon Young Song, Ki Tae Kwon, Wan Beom Park, Ji Yun Noh, Sun Hee Park, Eun Ju Choo, Min Joo Choi, Jun Yong Choi, Jung Yeon Heo, Won Suk Choi","doi":"10.3947/ic.2025.0033","DOIUrl":null,"url":null,"abstract":"<p><p>Annual influenza vaccination is strongly recommended for immunocompromised individuals, who are at a higher risk of severe infection. The Korean Society of Infectious Diseases has revised its influenza vaccination recommendations for solid organ transplant recipients, advocating for the use of highly immunogenic vaccines, such as high-dose inactivated influenza vaccines or MF59-adjuvanted inactivated influenza vaccines, to enhance vaccine efficacy. While further research is needed to extend these recommendations to other immunocompromised populations, these vaccines have demonstrated improved immunogenicity without compromising safety. Expanding vaccination guidelines to additional immunocompromised groups should be considered as more evidence emerges.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recommendations for Influenza Vaccination in Immunocompromised Patients.\",\"authors\":\"Joon Young Song, Ki Tae Kwon, Wan Beom Park, Ji Yun Noh, Sun Hee Park, Eun Ju Choo, Min Joo Choi, Jun Yong Choi, Jung Yeon Heo, Won Suk Choi\",\"doi\":\"10.3947/ic.2025.0033\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Annual influenza vaccination is strongly recommended for immunocompromised individuals, who are at a higher risk of severe infection. The Korean Society of Infectious Diseases has revised its influenza vaccination recommendations for solid organ transplant recipients, advocating for the use of highly immunogenic vaccines, such as high-dose inactivated influenza vaccines or MF59-adjuvanted inactivated influenza vaccines, to enhance vaccine efficacy. While further research is needed to extend these recommendations to other immunocompromised populations, these vaccines have demonstrated improved immunogenicity without compromising safety. Expanding vaccination guidelines to additional immunocompromised groups should be considered as more evidence emerges.</p>\",\"PeriodicalId\":51616,\"journal\":{\"name\":\"Infection and Chemotherapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infection and Chemotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3947/ic.2025.0033\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3947/ic.2025.0033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Recommendations for Influenza Vaccination in Immunocompromised Patients.
Annual influenza vaccination is strongly recommended for immunocompromised individuals, who are at a higher risk of severe infection. The Korean Society of Infectious Diseases has revised its influenza vaccination recommendations for solid organ transplant recipients, advocating for the use of highly immunogenic vaccines, such as high-dose inactivated influenza vaccines or MF59-adjuvanted inactivated influenza vaccines, to enhance vaccine efficacy. While further research is needed to extend these recommendations to other immunocompromised populations, these vaccines have demonstrated improved immunogenicity without compromising safety. Expanding vaccination guidelines to additional immunocompromised groups should be considered as more evidence emerges.